Treatment of Breast Cancer with 5-Fluorouracil

Ivy, Horace K.

doi:10.7326/0003-4819-57-4-598

Cited by 13 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There were areas of erythema and mild scale formation noted, particularly on the skin of the hands. The DNA synthesis "Dermatitis" has been seen in 3-19% of patients treated with systemic 5-FU (10)(11)(12)(13)(14).…”

Section: Discussionmentioning

confidence: 99%

Cicatricial ectropion secondary to 5‐fluorouracil therapy

Straus¹,

Mausolf²,

Ellerby³

et al. 1977

Med. Pediatr. Oncol.

View full text Add to dashboard Cite

Four cases of cicatricial ectropion secondary to prolonged systemic administration of 5-fluorouracil are described. In 1 patient ectropion resolved with conservative treatment and discontinuation of 5-FU. Another patient developed the ectropion terminally and died before its resolution. In 2 patients surgical repair of the ectropion was unsuccessful in relieving conjunctival symptoms while 5-FU was continued. With prolonged adjuvant chemotherapy programs utilizing 5-FU, this complication may be seen with increasing frequency. Conservative management should be attempted, and patients with this problem should be reassured that symptoms will resolve when 5-FU is stopped.

show abstract

Section: Discussionmentioning

confidence: 99%

Cicatricial ectropion secondary to 5‐fluorouracil therapy

Straus¹,

Mausolf²,

Ellerby³

et al. 1977

Med. Pediatr. Oncol.

View full text Add to dashboard Cite

show abstract

“…It is often said that hormonal measures are most effective in the control of metastases in bone but it should be remembered that whereas a relatively minor reduction in the volume of a bone secondary may be associated with the relief of pain, a comparable effect on metastases in soft tissues and organs may pass unnoticed. Chemotherapeutic agents are usually advocated for this type of disease and some success may be expected from thiotepa (Moore, 1958;Sears, 1961), methotrexate (Wright, Cobb, Golomb, Gumport, Lyall and Safadi, 1959) or 5-fluorouracil (Ivy, 1962;Dao and Grinberg, 1963) in 15-30% of patients.…”

Section: Hormonesmentioning

confidence: 99%

“…The most successful drugs in plasma-cell myeloma are cyclophosphamide (Matthias, Misiewicz and tary system has proved extremely resistant to therapy, although it is claimed that successful palliation may be achieved in 20-30% with 5-fluorouracil or related compounds (Wilson, 1960;Ansfield and Curreri, 1963 (Moore, 1958;Sears, 1961), methotrexate (Wright, Cobb, Golomb, Gumport, Lyall and Safadi, 1959) or 5-fluorouracil (Ivy, 1962;Dao and Grinberg, 1963) (Balme, 1954;Crile, 1957;Thomas, 1957 (Peters, 1950;Peters and Middlemiss, 1958).…”

mentioning

confidence: 99%